Sean Stalfort

Sean Stalfort was the founder of Benevolent Capital Partners LLC (Private Equity), founded in 2005, where the title held was Founding Partner from 2005 to 2010.
Mr. Stalfort is the founder of PBM Capital Group LLC, founded in 2010, holding the titles of Chairman and CEO since 2010.
Current jobs include Director at PBM Pharmaceuticals, Inc., Director at Tolerion, Inc., Director at Xalud Therapeutics, Inc., Director at Verrica Pharmaceuticals, Inc. since 2015, Board of Directors at Novartis Gene Therapies Switzerland GmbH, Independent Director at Taysha Gene Therapies, Inc. since 2023, Director at SalioGen Therapeutics, Inc., Director at Baxis Pharmaceuticals, Inc., Director at Vetana Animal Health, Inc., Independent Director at Acumen Pharmaceuticals, Inc. since 2018, Partner at Octagon Partners LLC, and Partner at Octagon Finance LLC.
Former jobs include Director at Perrigo Co., Director at Genapure Corp., Director at Candel Therapeutics, Inc., Director at Dova Pharmaceuticals, Inc. from 2016 to 2019, Director at Quantapore, Inc., Senior Underwriter at NatWest Markets Securities, Inc. in 2004, Vice President at Greenwich Capital Holdings, Inc. in 1996, Executive Vice President-New Business Development at PBM Products LLC, Investment Banking Associate at CS First Boston Pacific, Inc. in 1992, Senior Vice President-Capital Markets at Enterprise Mortgage Acceptance Co. LLC, Senior Vice President at Koch Financial Corp., and Founding Partner at Ravelin Capital Group LLC.
Education includes undergraduate degrees from Brown University, conferred in 1991, and the University of Massachusetts.